SCHEDULE 13G/A: Capital Research Global Investors Discloses 4.8% Passive Stake in BioMarin Pharmaceutical Inc.

Capital Research Global Investors, a division of Capital Research and Management Company, has filed an amended Schedule 13G disclosing a 4.8% beneficial ownership stake in BioMarin Pharmaceutical Inc. as of March 31, 2025.

Summary

• Capital Research Global Investors (CRGI) reported beneficial ownership of 9,150,655 shares of BioMarin Pharmaceutical Inc. common stock.
• This ownership represents 4.8% of BioMarin's outstanding common stock, based on 190,777,052 shares believed to be outstanding.
• CRGI holds sole voting power over 9,150,652 shares and sole dispositive power over 9,150,655 shares.
• The filing is an Amendment No. 2 to a previous Schedule 13G, indicating an update to their existing passive investment.
• CRGI is classified as an Investment Adviser (IA) and certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine regulatory disclosure of a passive ownership stake, providing no direct positive or negative operational or financial news about the company.

Positives

• The continued significant ownership by a major institutional investor like Capital Research Global Investors indicates ongoing institutional interest in BioMarin Pharmaceutical Inc.

Negatives

• The document does not contain any negative information regarding BioMarin Pharmaceutical Inc.'s operations or financial performance.

Risks

• The document does not detail specific risks related to BioMarin Pharmaceutical Inc.'s business operations or financial health, as it is a beneficial ownership report.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding BioMarin Pharmaceutical Inc.'s future performance or strategic direction.

Industry Context

This filing reflects a routine disclosure of a passive investment by a large asset manager in a publicly traded biotechnology company. It does not provide insights into broader industry trends or competitive dynamics beyond the specific ownership stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming their continued passive investment in the company.

Key Dates

Keywords

BioMarin Pharmaceutical Inc., Capital Research Global Investors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, BMRN